Details of the Drug Combination

General Information of Drug Combination (ID: DCCBF6F)

Drug Combination Name
RKI-1447 Marizomib
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs RKI-1447   DMGTAWC Marizomib   DME9QGW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 4.45
Bliss Independence Score: 3.84
Loewe Additivity Score: 2.65
LHighest Single Agent (HSA) Score: 2.88

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of RKI-1447
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
RKI-1447 Interacts with 8 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CDC42 binding protein kinase alpha (DMPK-like alpha) TT5Z0EF MRCKA_HUMAN Inhibitor [2]
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [2]
PAK-1 protein kinase (PAK1) TTFN95D PAK1_HUMAN Inhibitor [2]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [2]
Protein kinase N1 (PKN1) TTSL41O PKN1_HUMAN Inhibitor [2]
DMPK messenger RNA (DMPK mRNA) TTZQTY2 DMPK_HUMAN Inhibitor [2]
LIM domain kinase-1 (LIMK-1) TTWL9TY LIMK1_HUMAN Inhibitor [2]
Myosin light kinase (MYLK) TT18ETS MYLK_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTT(s)
Indication(s) of Marizomib
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 3 [3]
Malignant glioma 2A00.0 Phase 1 [4]
Multiple myeloma 2A83 Phase 1 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Marizomib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proteasome (PS) TTU7ZMG NOUNIPROTAC Inhibitor [6]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
3 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Triphase Accelerator .
6 Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.